tbuckley/cabot-search huggingface dataset:
Abstract 2043: The role of CCL20 in response to radiation in head and neck squamous cell carcinomas
Authors: Cleopatra Rutihinda, Ayman J. Oweida, Patrick Delage, Léanie Moreau, Safia Chelighem, Nour Elhouda Saidi
Journal: Cancer Research (2022)

Abstract Background: Radioresistance is responsible for most cases of tumor progression and recurrence in head and neck squamous cell carcinomas (HNSCC). Combined radiotherapy (RT) and immunotherapy (IT) treatment has improved survival for a minority of patients with inflamed tumors or tumors susceptible to RT-induced inflammation. To enhance the response of radioresistant tumors to radiation, an understanding of the factors that suppress anti-tumor immunity is necessary. In this regard, regulatory T cells (Tregs) are critical mediators of immune suppression in HNSCCs and their depletion improves tumor response to RT. In this study, we investigated how radiation modulates Treg infiltration through the chemokine CCL20. We hypothesized that radiation induces CCL20 secretion resulting in Treg infiltration and suppression of anti-tumor immunity and that blocking CCL20 could lead to improved response to RT. Methods: Human (Cal27, SCC9) and mouse (MOC1, MOC2) cell lines with different immune phenotypes were irradiated at doses of 2Gy or 10Gy. Conditioned media (CM), RNA and protein were collected for the assessment of CCL20. qPCR was used to determine CCL20 gene expression. In vivo, MOC2 cell were were implanted into the right buccal cavity of mice and the effect of neutralizing CCL20 antibody was determined alone and in combination with RT. Blood samples were collected before and after RT for the analysis of serum levels of CCL20. Tumor samples were analyzed by flow cytometry to determine immune infiltrates, including CD8 T cells and Tregs. Results: Cal27 and MOC2 tumors had a gene signature associated with immunosuppression and Treg infiltration whereas SCC9 and MOC1 tumors displayed a gene signature associated with an inflamed microenvironment. In vitro, high-dose radiation significantly induced CCL20 in Cal27 and MOC2 cells relative to control. Multiplex analysis of chemokines from conditioned media samples showed that induction of CCL20 was associated with increased secretion of GM-CSF by MOC2 and Cal27 cells. In vivo, inhibition of CCL20 alone resulted in a significant decrease in tumor growth compared to control in MOC2 tumors. The combination of RT and anti-CCL20 showed a significant decrease in tumor volume compared to RT alone. Conclusion: Our data suggests that high-dose radiation promotes the induction of CCL20 secretion by tumor cells which is responsible for attraction of Tregs. Inhibition of CCL20 secretion using anti-CCL20 antibodies can slow down tumor growth and enhance the response to radiation. Citation Format: Cleopatra Rutihinda, Ayman J. Oweida, Patrick Delage, Léanie Moreau, Safia Chelighem, Nour Elhouda Saidi. The role of CCL20 in response to radiation in head and neck squamous cell carcinomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2043.
Abstract 1759: PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma
Authors: Lei Wang, Haidong Liu, Xiao Shang, Tae Han, Baiteng Zhao
Journal: Cancer Research (2022)

Abstract PRO1160 is an antibody-drug conjugate directed toward CD70, an antigen that is aberrantly overexpressed in multiple hematologic malignancies and carcinomas with limited normal tissue expression. PRO1160 is comprised of a 1) human monoclonal antibody that selectively binds to CD70, 2) a cleavable, hydrophilic linker, and 3) exatecan, a topoisomerase 1 inhibitor. Upon binding to CD70 on the surface of malignant cells, PRO1160 is internalized and exatecan released through enzymatic cleavage of the linker. Exatecan blocks the ligation step of the cell cycle and generates DNA single- and double-strand breaks, which leads to cell death. PRO1160 demonstrated robust anti-tumor activity, in vitro and in vivo. In multiple cell-derived xenograft mouse models, PRO1160 demonstrated more potent tumor growth inhibition compared to an MMAE-conjugated ADC with the same parent antibody. PRO1160 was well tolerated in mice with no to minimal impact on body weight gain. The in vivo pharmacokinetics in rats showed that PRO1160 is stable in circulation. These nonclinical data suggest the potential for a broad therapeutic window and further development of PRO1160 is warranted. PRO1160 has the potential for an expanded therapeutic index. PRO1160 is being developed for the potential treatment of patients with CD70-expressing hematologic and solid tumor cancers. Citation Format: Lei Wang, Haidong Liu, Xiao Shang, Tae Han, Baiteng Zhao. PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1759.
Abstract 2319: Niclosamide enhances the antitumor effect by inducing ubiquitination of β-catenin in pancreatic cancer
Authors: HyeonWoong Kang, JoonSeong Park, YunSun Lee, Daeun Lee, HyoJung Kim
Journal: Cancer Research (2022)

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is known as one of the critical cancers that have a high morbidity and mortality worldwide. Due to lack of therapeutic agents, patients’ overall survival rate has been decreased. Gemcitabine is the only well-known drug to treat pancreatic cancer patients but less effective. Therefore, it is significantly required to discover and develop novel therapeutic agents for PDAC therapy. The present study represents the first study evaluating the anticancer efficacy of niclosamide in PDAC. Here, we found that niclosamide co-treatment with gemcitabine inhibited pancreatic cancer cells compared with gemcitabine alone by suppressing the Wnt/β-catenin signaling pathway. In addition, niclosamide co-treatment with gemcitabine inhibited cell proliferation as determined by MTS assay and induced cell apoptosis as determined by Annexin V and PI staining. Further, niclosamide induced G1 arrest of the cell cycle as evidenced by down-regulated CDK4/6 and Cyclin D1 expression. Our findings proved that combining niclosamide and Gemcitabine effectively down-regulates the tumor size and growth in pancreatic cancer. Altogether, our results indicate that niclosamide synergistically enhances the antitumor effect with treating gemcitabine by inducing the ubiquitination and degradation of β-catenin in pancreatic cancer and could be a novel potential candidate for PDAC therapy.Key words: PDAC, Niclosamide, Gemcitabine, β-catenin ubiquitination, Apoptosis, Cell cycle Citation Format: HyeonWoong Kang, JoonSeong Park, YunSun Lee, Daeun Lee, HyoJung Kim. Niclosamide enhances the antitumor effect by inducing ubiquitination of β-catenin in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2319.
Abstract 3118: Functional characterization and therapeutic response differences between orthotopic and subcutaneous patient-derived xenograft models
Authors: Jonathan Nakashima, Long Do, Warren Andrews, Yuan-Hung Chien, Christophe Pedros, Jantzen Sperry, Bianca Carapia, Deborah Yan, Giovanni Rivera, Arun Singh, Fritz C. Eilber, Brian Datnow
Journal: Cancer Research (2022)

Abstract Subcutaneous patient-derived xenografts (PDXs) have provided the research community with translational models to interrogate cancer biology and assist in drug development. Orthotopic PDXs provide an even more clinically relevant model system that recapitulates the tumor environment aspects of the human disease. Here, we compare the differences in gene expression signatures of PDX models when implanted subcutaneously or orthotopically. Furthermore, we evaluate differences in in-vivo pharmacological response between the two model systems and identify several functional characterizations that selectively enhance pharmacological response in favor of the orthotopic model. Citation Format: Jonathan Nakashima, Long Do, Warren Andrews, Yuan-Hung Chien, Christophe Pedros, Jantzen Sperry, Bianca Carapia, Deborah Yan, Giovanni Rivera, Arun Singh, Fritz C. Eilber, Brian Datnow. Functional characterization and therapeutic response differences between orthotopic and subcutaneous patient-derived xenograft models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3118.
Abstract LB014: Carbon monoxide induced PERK regulated autophagy reprograms anti-tumor T cells with robust immunometabolic phenotype
Authors: Paramita Chakraborty, Rasesh Y. Parikh, Seungho Choi, Meenal Mehrotra, Eduardo N. Maldonado, Hongjun Wang, J. Alan Diehl, Vamsi K. Gangaraju, Shikhar Mehrotra
Journal: Cancer Research (2022)

Abstract Mitochondria and Endoplasmic reticulum (ER) share structural and functional networks to maintain cellular homeostasis and activate well-orchestrated signaling processes to shape cells' fate and function. While persistent ER stress (ERS) response leads to mitochondrial collapse, moderate ERS condition drives mitochondrial biogenesis and function. So far, various strategies have been tested to enhance the mitochondrial function in T cells to improve their anti-tumor potential. However, strategies targeting ER-Mitochondria crosstalk (by employing moderate ERS condition) to boost the anti-tumor T cell function have not been exploited yet. Thus, in the present study, we used carbon monoxide (CO), a short-lived gaseous molecule, to test if engaging moderate ERS conditions can improve T cells mitochondrial biogenesis, function, and anti-tumor therapeutic efficacy. Using melanoma antigen gp100 reactive T cells, we identify that CO induced transient activation of ERS sensor ‘protein kinase R-like endoplasmic reticulum kinase (PERK)’ dramatically increase anti-tumor T cell function. Furthermore, mechanistically we found that CO-induced PERK activation temporarily halts protein translation and induces protective autophagy (that includes mitophagy). To get further insight into how CO treatment kinetically regulates autophagic activity in T cells, we used LC3-GFP to differentiate between the cells that prepare themselves to undergo active autophagy (LC3-GFPpos) and those that fail to enter into the process (LC3-GFPneg). Using Ag-specific LC3-GFP expressing T cells, we demonstrate that LC3-GFPpos T cells show robust anti-tumor potential. Moreover, LC3-GFPneg shows a T regulatory-like phenotype, harbors dysfunctional mitochondria, and accumulates abnormal metabolite content. These anomalous ratios of metabolites render the cells with a hypermethylated state and distinct epigenetic profile limiting their anti-tumor activity. Overall, this preclinical data highlights that ERS-mediated activation of autophagy pathways modifies the mitochondrial function and epigenetically reprogram the T cells towards a superior anti-tumor phenotype and can be therapeutically translated to achieve robust tumor control in adoptive transfer therapies. Citation Format: Paramita Chakraborty, Rasesh Y. Parikh, Seungho Choi, Meenal Mehrotra, Eduardo N. Maldonado, Hongjun Wang, J. Alan Diehl, Vamsi K. Gangaraju, Shikhar Mehrotra. Carbon monoxide induced PERK regulated autophagy reprograms anti-tumor T cells with robust immunometabolic phenotype [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB014.
Abstract 1086: PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma
Authors: Vanessa Del Pozo, Andrew J. Robles, Shaun Fontaine, Qianqian Liu, Joel E. Michalek, Peter J. Houghton, Raushan Kurmasheva
Journal: Cancer Research (2022)

Abstract Introduction: The Ewing family of sarcomas is the fourth most common highly malignant childhood cancer. Current standard therapy is relatively ineffective for relapsed and metastatic Ewing sarcoma predominantly due to development of resistance to chemotherapeutics. Nanoparticle-formulated drugs are reported to increase uptake into tumor tissue, while reducing drug access to normal tissues, because of reduced permeability of normal vasculature. This potentially leads to lower dose exposure in normal tissues and reduced toxicity. The purpose of this study was to evaluate the antitumor activity of the PEGylated poly(ADP) ribose polymerase 1/2 (PARP1/2) inhibitor talazoparib combined with the DNA alkylating agent temozolomide (TMZ) in Ewing sarcoma xenograft models and other pediatric cancers. Method:. We evaluated the preclinical efficacy of PEGylated talazoparib (PEG~TLZ), alone or in combination with TMZ, in Ewing sarcoma and glioblastoma patient derived xenograft (PDX) models. Additional solid tumor models, such as rhabdomyosarcoma, Wilms tumor, malignant rhabdoid tumor, osteosarcoma, and synovial sarcoma were evaluated using a novel single mouse testing approach. PEG~TLZ was administered as a single administration intraperitoneally to mice bearing subcutaneous tumors at a single dose of 5 - 20 µmol/kg alone, or at 10 µmol/kg on day 1 combined with TMZ administered orally at 40 mg/kg starting on day 3 or 4 for 5 consecutive days. Results: Mice bearing Ewing sarcoma and MGMT-deficient glioblastoma xenografts tolerated PEG~TLZ+TMZ with minimal toxicity and achieved maintained complete response (MCR). The time-separated drug administration schedule of the single dose of PEG~TLZ followed by the 5-day TMZ treatment demonstrated objective responses in Ewing sarcoma, rhabdoid tumor, rhabdomyosarcoma, and glioblastoma PDX models. Conclusion: We evaluated the range of PEG~TLZ+TMZ activity among pediatric solid tumor panels using conventional and single-mouse testing approaches, and demonstrated that PEG~TLZ combined with delayed TMZ administration enhances the therapeutic window of the treatment compared to free TLZ. From the clinical standpoint, the single intravenous administration of PEG~TLZ could be advantageous for treating infants and young children. Citation Format: Vanessa Del Pozo, Andrew J. Robles, Shaun Fontaine, Qianqian Liu, Joel E. Michalek, Peter J. Houghton, Raushan Kurmasheva. PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1086.
Abstract 3287: Baseline CD166 expression determines CRISPR-mediated <i>ALCAM</i> gene knockout effects on migratory phenotype in metastatic melanoma cells
Authors: Rafal Kaminski, Francesca P. Luongo, Konrad Dabrowski, Anna Bellizzi, Pietro Mancuso, M. Raza Zaidi, Johanna McMillan, Meha Patel, Tyrone Coleman, Oneida A. Arosarena
Journal: Cancer Research (2022)

Abstract Advanced stage melanoma is a mostly incurable, highly aggressive tumor whose incidence is rising. Metastatic dissemination of primary tumors involves the repeated crossing of tissues barriers, which requires dynamic modulation of tumor cell adhesion, presumably through mechanisms like those utilized by trafficking leukocytes. Activated leukocyte cell adhesion molecule (ALCAM/CD166) has been shown to play an important role in the metastatic process, including detachment from the primary tumor, adhesion to endothelium, and extravasation. ALCAM expression correlates with melanoma progression, and it has been identified as a marker of pluripotent stem cells. Furthermore, its expression in primary melanoma strongly correlates with tumor thickness and level of invasiveness. shRNA silencing of ALCAM in cells with high levels of ALCAM resulted in reduced motility and transmigration. In the current study, we tested the effect of CRISPR-mediated ALCAM knockout (KO) on migration and invasion of two human melanoma cell lines representing opposite phenotypic states of melanoma. MEL501 (proliferative type, SOX10/MITF-high and AP1/TEAD1-low) cells express low levels of ALCAM at baseline, while the Rosi cell line (invasive type, SOX10/MITF-low and AP1/TEAD1-high) expresses high baseline ALCAM levels. ALCAM KO promoted migration of MEL501 cells (p&amp;lt;0.000001) but inhibited migration of Rosi cells (p=0.005050) as compared to the parent cell lines. In addition, ALCAM KO promoted the invasion of MEL501 cells (p=0.019768) but had no impact on Rosi cell invasion. While ALCAM has been shown to regulate matrix metalloproteinase-2 (MMP-2) activation, zymograms revealed no difference in MMP-2 activity between MEL501 and Rosi ALCAM-KO cells and the parent cell lines. These data indicate that ALCAM may play a tumor-suppressive role in melanoma cells with low ALCAM expression and are consistent with a previous study which demonstrated that introduction of an amino-terminally truncated ALCAM in early stage melanoma cells promoted metastasis. Our data also provide in vitro evidence that gene therapy may reverse the migratory phenotype of melanoma cells with high ALCAM expression. Citation Format: Rafal Kaminski, Francesca P. Luongo, Konrad Dabrowski, Anna Bellizzi, Pietro Mancuso, M. Raza Zaidi, Johanna McMillan, Meha Patel, Tyrone Coleman, Oneida A. Arosarena. Baseline CD166 expression determines CRISPR-mediated ALCAM gene knockout effects on migratory phenotype in metastatic melanoma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3287.
Abstract 1626: The orthotopic mouse study of cetuximab and dasatinib treatment on BRAF mutated colon cancer cells
Authors: Yu-Cheng Weng, Yu-Lin Li, Xiang-Ling Hou, Hui Min Koo, Yi-Wen Lu, Viriya Adhiguna Winarso, Chia-Wen Lin, Wei-Ting Chao
Journal: Cancer Research (2022)

Abstract Colorectal cancer is one of the most common cancer in the world. The mortality rate is the third among the top ten cancers. Among colorectal cancer patients, about 65-75% of patients have overexpression of epithelial growth factor receptors (EGFR). The antibody drug cetuximab that inhibits EGFR has also been developed. Moreover, overexpression of src protein is found in about 80% of patients with colorectal cancer. Higher levels of Src expression is related to the metastasis of colon cancer. Dasatinib is an oral taken tyrosine kinase inhibitor to inhibit the src phosphorylation. Therefore, in this study, the mechanism of cetuximab and dasatinib combined treatment in the orthotopic mouse model is investigated. The in vivo mechanism of EGFR and E-cadherin crosstalk in the mouse model is discussed. In this study, HT-29 colon cancer cells with BRAF V600E mutation were orthotopically injected into the cecum wall of BALB/c nude male mice. Two weeks later, cetuximab, dasatinib, and combined treatment of cetuximab and dasatinib were applied for three weeks. The tumor sizes were then recorded after sacrificed. Tumor Tissue were processed for tissue section with H&amp;E staining. Immunohistochemistry (IHC) was applied to detect EGFR, p-Src, E-cadherin with specific antibodies. The protein expression levels were achieved by Western blot. In the results, the tumor size was smaller in cetuximab and dasatinib combined treated group. In IHC staining, the E-cadherin expression were not apparent in primary tumor site, however, were abundant in migrated cells. P-src expression was reduced in the dasatinib treated group and combined treatment group. In western blot result, the E-cadherin was increased after the treatment of dasatinib, and the p-src expression was inhibited after dasatinib treatment and combined treatment. Our results demonstrated cetuximab combined with dasatinib has the better result of suppression of BRAF mutated colon cancer cell growth and metastasis in the orthotopic mouse model. Citation Format: Yu-Cheng Weng, Yu-Lin Li, Xiang-Ling Hou, Hui Min Koo, Yi-Wen Lu, Viriya Adhiguna Winarso, Chia-Wen Lin, Wei-Ting Chao. The orthotopic mouse study of cetuximab and dasatinib treatment on BRAF mutated colon cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1626.
Abstract 2402: SMAD4 represses PDAC metastatic colonization through binding FOSL1 enhancer regions
Authors: Jonathan P. Rennhack, Chao Dai, Andrew Aguirre, John Doench, David Root, William C. Hahn
Journal: Cancer Research (2022)

Abstract Less than 5% of patients diagnosed with pancreatic ductal adenocarcinomas (PDAC) survive more than 5 years, largely due to therapeutic resistance and metastatic disease. Half of all PDAC patients have been shown to have loss of SMAD4, which has been shown to correlate with metastasis. Here we functionally demonstrate that SMAD4 is a key suppressor of metastatic colonization of PDAC. Using an in vitro and in vivo multi-component RNA-seq analysis on isogenic human PDAC cell lines, we defined SMAD4-dependent gene expression changes. Specifically, we identified genes that were suppressed in the presence of SMAD4. These genes could contribute to tumor metastasis. To test this, we performed a pooled open reading frame (ORF) overexpression lung colonization assay with the identified genes. We found that expression of the transcription factor FOSL1 is sufficient for metastatic colonization. Mechanistically, SMAD4 directly binds and modulates the activity of the FOSL1 enhancer. Taken together, these studies demonstrate a direct role for SMAD4 in regulating metastatic colonization and identify FOSL1 as a direct SMAD4-regulated gene involved in distant site colonization. Citation Format: Jonathan P. Rennhack, Chao Dai, Andrew Aguirre, John Doench, David Root, William C. Hahn. SMAD4 represses PDAC metastatic colonization through binding FOSL1 enhancer regions [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2402.